Lukas Bubendorf
Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer.
Vlajnic T, Muller D, Ruiz C, Schönegg R, Seifert H, Thalmann G, Zellweger T, Le Magnen C, Rentsch C, Bubendorf L. Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer. Cancer Rep (Hoboken) 2023:e1953.
Dec 26, 2023Exploring the intratumoral heterogeneity of DNA ploidy in prostate cancer.
Dec 26, 2023Cancer Rep (Hoboken) 2023:e1953
Vlajnic Tatjana, Muller David C, Ruiz Christian, Schönegg René, Seifert Hans-Helge, Thalmann George N, Zellweger Tobias, Le Magnen Clémentine, Rentsch Cyrill A, Bubendorf Lukas
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel R, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. J Clin Oncol 2023; 41:5131-5139.
Aug 17, 2023Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Aug 17, 2023J Clin Oncol 2023; 41:5131-5139
Cathomas Richard, Rothschild Sacha I, Hayoz Stefanie, Bubendorf Lukas, Özdemir Berna C, Kiss Bernhard, Erdmann Andreas, Aeppli Stefanie, Mach Nicolas, Strebel Räto T, Hadaschik Boris, Berthold Dominik R, John Hubert, Zihler Deborah, Schmid Mathias, Alborelli Ilaria, Schneider Martina, Musilova Jana, Spahn Martin, Petrausch Ulf
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Schmitt-Opitz I, Guckenberger M, Früh M, Betticher D, Ris H, Stupp R, Rothschild S, Bubendorf L, Pless M. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO Open 2023; 8:101595.
Jul 11, 2023Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
Jul 11, 2023ESMO Open 2023; 8:101595
König Dietmar-Pierree, Savic Prince Spasenija, Hayoz Stefanie, Zens P, Berezowska Sabina, Jochum Wolfram, Stauffer Edouard, Braunersreuther V, Trachsel B, Thierstein Sandra, Mark Michael Thomas, Schmid Sebastian M, Curioni-Fontecedro Alessandra, Addeo Alfredo, Schmitt-Opitz Isabelle, Guckenberger Matthias, Früh Martin, Betticher Daniel C, Ris H B, Stupp Roger, Rothschild Sacha I, Bubendorf Lukas, Pless Miklos
DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations.
Gallon J, Rodriguez-Calero A, Benjak A, Akhoundova D, Maletti S, Amstutz U, Hewer E, Genitsch V, Fleischmann A, Rushing E, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya A, Bubendorf L, Moch H, Thalmann G, Feng F, Gillessen S, Chiang C, Rubin M, Piscuoglio S. DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations. Cancer Res 2023; 83:1203-1213.
Apr 14, 2023DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations.
Apr 14, 2023Cancer Res 2023; 83:1203-1213
Gallon John, Rodriguez-Calero Antonio, Benjak Andrej, Akhoundova Dilara, Maletti Sina, Amstutz Ursula, Hewer Ekkehard, Genitsch Vera, Fleischmann Achim, Rushing Elisabeth Jane, Grobholz Rainer, Fischer Ingeborg, Jochum Wolfram, Cathomas Gieri, Osunkoya Adeboye O, Bubendorf Lukas, Moch Holger, Thalmann George N, Feng Felix Y, Gillessen Silke, Chiang Charleston W K, Rubin Monika Afzali, Piscuoglio Salvatore
Alterations in homologous recombination repair genes in prostate cancer brain metastases.
Rodriguez-Calero A, Gallon J, Akhoundova D, Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V, Tomlins S, Hewer E, Genitsch V, Fleischmann A, Vassella E, Rushing E, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya A, Bubendorf L, Moch H, Thalmann G, Ng C, Gillessen S, Piscuoglio S, Rubin M. Alterations in homologous recombination repair genes in prostate cancer brain metastases. Nat Commun 2022; 13:2400.
May 3, 2022Alterations in homologous recombination repair genes in prostate cancer brain metastases.
May 3, 2022Nat Commun 2022; 13:2400
Rodriguez-Calero Antonio, Gallon John, Akhoundova Dilara, Maletti Sina, Ferguson Alison, Cyrta Joanna, Amstutz Ursula, Garofoli Andrea, Paradiso Viola, Tomlins Scott A, Hewer Ekkehard, Genitsch Vera, Fleischmann Achim, Vassella Erik, Rushing Elisabeth J, Grobholz Rainer, Fischer Ingeborg, Jochum Wolfram, Cathomas Gieri, Osunkoya Adeboye O, Bubendorf Lukas, Moch Holger, Thalmann George, Ng Charlotte K Y, Gillessen Silke, Piscuoglio Salvatore, Rubin Mark A
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Rentsch C, Roth B, Bosshard P, Püschel H, Boll D, Hefermehl L, Roghmann F, Gierth M, Ribi K, Schäfer S, Wicki A, Bubendorf L, Torpai R, Thalmann G, Lucca I, Kwiatkowski M, Wirth G, Strebel R, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Hayoz S. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. Eur Urol Oncol 2022; 5:195-202.
Jan 7, 2022A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
Jan 7, 2022Eur Urol Oncol 2022; 5:195-202
Rentsch Cyrill A, Roth Beat, Bosshard Piet, Püschel Heike, Boll Daniel T, Hefermehl Lukas, Roghmann Florian, Gierth Michael, Ribi Karin, Schäfer Simon, Wicki Andreas, Bubendorf Lukas, Torpai Raimund, Thalmann George N, Lucca Ilaria, Kwiatkowski Maciej, Wirth Grégory J, Strebel Räto T, Engeler Daniel, Pedrazzini Augusto, Hüttenbrink Clemens, Schultze-Seemann Wolfgang, Hayoz Stefanie
Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study
Fuchs J, Früh M, Papachristofilou A, Bubendorf L, Häuptle P, Jost L, Zippelius A, Rothschild S. Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study. PloS one 2021; 16:e0253601.
Jun 28, 2021Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study
Jun 28, 2021PloS one 2021; 16:e0253601
Fuchs Julia, Früh Martin, Papachristofilou Alexandros, Bubendorf Lukas, Häuptle Pirmin, Jost Lorenz, Zippelius Alfred, Rothschild Sacha I
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Hench I, Vlajnic T, Bubendorf L, Burg P, Tolnay M, Ruiz C, Rothermundt C, Püschel H, Mestre R, Mingrone W, Kremer E, Hermanns T, Hench J, Gillessen Sommer S, Fischer N, Costa L, Cathomas R, Sakk S. Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). Cancers (Basel) 2019; 11
Aug 1, 2019Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Aug 1, 2019Cancers (Basel) 2019; 11
Hench Ivana Bratic, Vlajnic Tatjana, Bubendorf Lukas, Burg Philippe Von, Tolnay Markus, Ruiz Christian, Rothermundt Christian, Püschel Heike, Mestre Ricardo Pereira, Mingrone Walter, Kremer Eloïse, Hermanns Thomas, Hench Jürgen, Gillessen Sommer Silke, Fischer Natalie, Costa Luigi, Cathomas Richard, Sakk Swiss Group For Clinical Cancer Research
PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study
Savic S, Soltermann A, Zweifel R, Zettl A, von Gunten M, Singer G, Rössle M, Jasarevic Z, Letovanec I, McKee T, Komminoth P, Jochum W, Fleischmann A, Diebold J, Cathomas G, Eppenberger-Castori S, Berezowska S, Bubendorf L. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. Virchows Arch 2019; 475:67-76.
May 24, 2019PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study
May 24, 2019Virchows Arch 2019; 475:67-76
Savic Spasenija, Soltermann Alex, Zweifel Roland, Zettl Andreas, von Gunten Michael, Singer Gad, Rössle Matthias, Jasarevic Zerina, Letovanec Igor, McKee Thomas, Komminoth Paul, Jochum Wolfram, Fleischmann Achim, Diebold Joachim, Cathomas Gieri, Eppenberger-Castori Serenella, Berezowska Sabina, Bubendorf Lukas
Prognostic value of MIB-1 proliferation index in solitary fibrous tumors of the pleura implemented in a new score - a multicenter study
Diebold M, Kohler M, Oezkan F, Darwiche K, Berezowska S, Theegarten D, Grobholz R, Jochum W, Komminoth P, Bubendorf L, Haile S, Hottinger S, Soltermann A, Franzen D. Prognostic value of MIB-1 proliferation index in solitary fibrous tumors of the pleura implemented in a new score - a multicenter study. Respir Res 2017; 18:210.
Dec 16, 2017Prognostic value of MIB-1 proliferation index in solitary fibrous tumors of the pleura implemented in a new score - a multicenter study
Dec 16, 2017Respir Res 2017; 18:210
Diebold Matthias, Kohler Malcolm, Oezkan Filiz, Darwiche Kaid, Berezowska Sabina, Theegarten Dirk, Grobholz Rainer, Jochum Wolfram, Komminoth Paul, Bubendorf Lukas, Haile Sarah R, Hottinger Selma, Soltermann Alex, Franzen Daniel P
Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended
Savic S, Kerr K, Bisig B, Tornillo L, Grieshaber S, Baschiera B, Jochum W, Zimmermann A, Diebold J, Bubendorf L. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer 2015; 89:104-9.
May 21, 2015Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended
May 21, 2015Lung Cancer 2015; 89:104-9
Savic Spasenija, Kerr Keith, Bisig Bettina, Tornillo Luigi, Grieshaber Susanne, Baschiera Betty, Jochum Wolfram, Zimmermann Anne-Katrin, Diebold Joachim, Bubendorf Lukas
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
Mar 5, 2015Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Mar 5, 2015Clin Lung Cancer 2015; 16:358-65
Gautschi Oliver, Savic Spasenija, Jaggi Rolf, Leibundgut Elisabeth Oppliger, Largiadèr Carlo, Brutsche Martin, Pilop Christiane, Stalder Lukas, Pless Miklos, Ochsenbein Adrian F, Bubendorf Lukas, Feilchenfeldt Jonas, Rauch Daniel, Mach Nicholas, Rothschild Sacha I, Li Qiyu, Stahel Rolf A, Zippelius Alfred, Cathomas Richard, Früh Martin, Betticher Daniel C, Peters Solange, Swiss Group for Clinical Cancer Research
EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Baty F, Brutsche M, Pless M, Zappa F, Crowe S, Bubendorf L, Gautschi O, Rauch D, Cathomas R, Dröge C, Betticher D, Früh M, Rothschild S, Swiss Group for Clinical Cancer Research. EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PloS one 2013; 8:e72966.
Sep 10, 2013EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
Sep 10, 2013PloS one 2013; 8:e72966
Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Crowe Susanne, Bubendorf Lukas, Gautschi Oliver, Rauch Daniel, Cathomas Richard, Dröge Cornelia, Betticher Daniel, Früh Martin, Rothschild Sacha, Swiss Group for Clinical Cancer Research
Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Holbro A, Lehmann T, Girsberger S, Stern M, Gambazzi F, Lardinois D, Heim D, Passweg J, Tichelli A, Bubendorf L, Savic S, Hostettler K, Grendelmeier P, Halter J, Tamm M. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19:973-80.
Apr 2, 2013Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Apr 2, 2013Biol Blood Marrow Transplant 2013; 19:973-80
Holbro Andreas, Lehmann Thomas, Girsberger Sabine, Stern Martin, Gambazzi Franco, Lardinois Didier, Heim Dominik, Passweg Jakob R, Tichelli André, Bubendorf Lukas, Savic Spasenija, Hostettler Katrin, Grendelmeier Peter, Halter Joerg P, Tamm Michael
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer 2012; 79:59-64.
Nov 1, 2012VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Nov 1, 2012Lung Cancer 2012; 79:59-64
Gautschi Oliver, Stahel Rolf, Carbone David, Na Kyung-Jae, Hsu Schmitz Shu-Fang, Bubendorf Lukas, Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Roder Joanna, Grigorieva Julia, Roder Heinrich, Peters Solange, Crowe Susanne, Dingemans Anne-Marie, Smit Egbert
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012; 18:6049-57.
Sep 12, 2012Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Sep 12, 2012Clin Cancer Res 2012; 18:6049-57
Cathomas Richard, Gillessen Sommer Silke, von Moos Roger, Schiess Ralph, Pless Miklos, Berthold Dominik R, Siciliano Daniele, Winterhalder Ralph, Droege Cornelia, Cotting Denise, Brauchli Peter, Betticher Daniel C, Jaggi Rolf, Bubendorf Lukas, Klingbiel Dirk, Rothermundt Christian, Swiss Group for Clinical Cancer Research SAKK
Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology
Tapia C, Glatz K, Obermann E, Grilli B, Barascud A, Herzog M, Schönegg R, Savic S, Bubendorf L. Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology. Cancer Cytopathol 2011; 119:404-10.
Jul 5, 2011Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology
Jul 5, 2011Cancer Cytopathol 2011; 119:404-10
Tapia Coya, Glatz Kathrina, Obermann Ellen C, Grilli Bruno, Barascud Audrey, Herzog Michelle, Schönegg René, Savic Spasenija, Bubendorf Lukas
Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology
Savic S, Herman J, Clark D, Zlobec I, Schönegg R, Spieler P, Loosli H, Bode B, Herzog M, Barascud A, Grilli B, Franco N, Bubendorf L. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest 2010; 138:137-44.
Feb 5, 2010Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology
Feb 5, 2010Chest 2010; 138:137-44
Savic Spasenija, Herman James G, Clark Douglas P, Zlobec Inti, Schönegg René, Spieler Peter, Loosli Heinz, Bode Beata, Herzog Michelle, Barascud Audrey de Vito, Grilli Bruno, Franco Noreli, Bubendorf Lukas
Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer
Baty F, Tamm M, Kehren J, Buess M, Budach W, Marrer E, Savic S, Bubendorf L, Pless M, Schumacher M, Kaiser S, Facompre M, Brutsche M. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. American journal of respiratory and critical care medicine 2010; 181:181-8.
Jan 15, 2010Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer
Jan 15, 2010American journal of respiratory and critical care medicine 2010; 181:181-8
Baty Florent, Tamm Michael, Kehren Jeanne, Buess Martin, Budach Wolfgang, Marrer Estelle, Savic Spasenija, Bubendorf Lukas, Pless Miklos, Schumacher Martin, Kaiser Sergio, Facompre Michael, Brutsche Martin
Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens
Zlobec I, Raineri I, Schneider S, Schönegg R, Grilli B, Herzog M, Savic S, Bubendorf L. Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. Lung cancer (Amsterdam, Netherlands) 2009
Jul 17, 2009Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens
Jul 17, 2009Lung cancer (Amsterdam, Netherlands) 2009
Zlobec Inti, Raineri Ines, Schneider Sandra, Schönegg René, Grilli Bruno, Herzog Michelle, Savic Spasenija, Bubendorf Lukas